SCHEMBL284242

SCHEMBL284242

CC(C)(C)c1ccc(C(N)=O)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.66
NR1H4 Q96RI1 1/20 0.66
ESRRG P62508 1/20 0.62
HDAC1 Q13547 1/20 0.59
SRD5A2 P31213 1/20 0.57
ALDH1A1 P00352 3/20 0.52
MEN1 O00255 2/20 0.52
HTT P42858 2/20 0.52
KMT2A Q03164 2/20 0.52
MAPT P10636 2/20 0.52
HIF1A Q16665 1/20 0.52
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
POLB P06746 1/20 0.52
RARB P10826 1/20 0.52
RARG P13631 1/20 0.52
DHODH Q02127 1/20 0.50
KIF11 P52732 1/20 0.50
TNF P01375 1/20 0.50
KLF5 Q13887 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5012511 0.98 EPHX2 (0.64) EPHX2NR1H4ESRRGHDAC1SRD5A2
SCHEMBL17806562 0.94 EPHX2 (0.60) EPHX2NR1H4ESRRGHDAC1SRD5A2
SCHEMBL4671943 0.88 PARP10 (0.70) EPHX2NR1H4ESRRGALDH1A1KMT2A
SCHEMBL27989128 0.86 EPHX2 (0.51) EPHX2NR1H4ESRRGHDAC1SRD5A2
SCHEMBL28573695 0.85 EPHX2 (0.60) EPHX2NR1H4ESRRGHDAC1SRD5A2
SCHEMBL7302042 0.85 HDAC3 (0.73) EPHX2NR1H4MEN1KMT2ANPC1
SCHEMBL1019153 0.84 EPHX2 (0.50) EPHX2NR1H4ESRRGHDAC1SRD5A2
SCHEMBL17292714 0.84 NR1H4 (0.51) EPHX2NR1H4ESRRGHDAC1SRD5A2
SCHEMBL11583494 0.82 HDAC1 (0.55) EPHX2NR1H4ESRRGHDAC1SRD5A2
SCHEMBL2677683 0.82 EPHX2 (0.49) EPHX2NR1H4ESRRGHDAC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1063 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119371298-A Method for efficiently synthesizing indenone compound 南阳师范学院 2025-01-28 CN claimed
WO-2025009910-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF 부산대학교 산학협력단 2025-01-09 WO claimed
CN-118344283-A Trifluoromethyl unit-containing substituted 2-piperidone compound and synthesis method thereof 西南交通大学 2024-07-16 CN claimed
CN-115724780-A Acyl thiourea compound based on hydrophobic label, preparation method thereof and application of acyl thiourea compound in resisting influenza A virus 武汉大学 2023-03-03 CN claimed
EP-1773768-B1 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2018-08-22 EP claimed
EP-3280419-A1 INDAZOLE AND AZAINDAZOLE BTK INHIBITORS Merck Sharp & Dohme Corp. (US) 2018-02-14 EP claimed
EP-1656144-B2 TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS GENENTECH INC (US) 2017-12-20 EP claimed
WO-2016164285-A1 INDAZOLE AND AZAINDAZOLE BTK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-10-13 WO claimed
US-20150274661-A1 INDOL-AMIDE COMPOUNDS AS BETA-AMYLOID INHBITORS HOFFMANN-LA ROCHE INC. (US) 2015-10-01 US claimed
EP-2909190-A1 INDOL-AMIDE COMPOUNDS AS BETA-AMYLOID INHBITORS F. Hoffmann-La Roche AG (CH) 2015-08-26 EP claimed
EP-1007037-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 2000-06-14 EP claimed
EP-0999834-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 2000-05-17 EP claimed
WO-2000025768-A1 OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF TREGA BIOSCIENCES, INC. (US) 2000-05-11 WO claimed
WO-1999000128-A9 ANTITHROMBOTIC AGENTS LILLY CO ELI (US) 1999-08-05 WO claimed
WO-1999000128-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 1999-01-07 WO claimed
WO-1999000121-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 1999-01-07 WO claimed
WO-1999000126-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 1999-01-07 WO claimed
WO-1999000127-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 1999-01-07 WO claimed
US-5409808-A Excellent sensitivity and gradation; improved storage stability FUJI PHOTO FILM CO., LTD. (JP) 1995-04-25 US claimed
WO-1994005642-A1 INDAZOLE DERIVATIVES CIBA-GEIGY AG (CH) 1994-03-17 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150274661-A1 INDOL-AMIDE COMPOUNDS AS BETA-AMYLOID INHBITORS APP, BACE1, IAPP EPHX2 2108/4885NR1H4 761/4885ESRRG 2243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.